information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L’Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: July 8, 1996.

Bob Sargis,
Acting Director, Office of Information Services.

Federal Register / Vol. 61, No. 135 / Friday, July 12, 1996 / Notices

Proposed Information Collection Activity; Comment Request

Title: ACF Uniform Discretionary Grant Application Form.
OMB No.: 0970–0139.
Description: ACF has more than forty discretionary grant programs. The proposed information collection form would be a uniform discretionary application form usable for all of these grant programs to collect the information from grant applicants needed to evaluate and rank applicants and protect the integrity of the grantee selection process. All ACF discretionary grant programs would be eligible but not required to use this application form. The application consists of general information and instructions; the Standard Form 424 series that requests basic information, budget information and assurances; the Program Narrative requesting the applicant to describe how these objectives will be reached; and certifications. Guidance for the content of information requested in the Program Narrative is found in OMB Circulars A–102 and A–110.

Respondents: State governments.

ANNUAL BURDEN ESTIMATES

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Form</td>
<td>4,127</td>
<td>1</td>
<td>4</td>
<td>16,688</td>
</tr>
</tbody>
</table>

Estimated Total Annual Burden Hours: 16,688.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L’Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: July 9, 1996.

Bob Sargis,
Acting Director, Office of Information Services.

Food and Drug Administration

Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the renewal of the Transmissible Spongiform Encephalopathies Advisory Committee (formerly Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease) by the Commissioner of Food and Drugs. The Commissioner has determined that it is in the public interest to renew the charter of the Committee for an additional 2 years. At the time of charter renewal, the Committee’s name and function were changed to more accurately describe the Committee and because the Committee is no longer serving in an ad hoc capacity. Elsewhere in this issue of the Federal Register the agency is issuing a final rule that announces the addition of the Transmissible Spongiform Encephalopathies Advisory Committee to the agency’s list of standing advisory committees (21 CFR 14.100). This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463 (5 U.S.C. app.2)).

DATES: Authority for this committee will expire on June 9, 1998, unless the Commissioner formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: July 5, 1996.

Michael A. Friedman,
Deputy Commissioner for Operations.

Federal Register / Vol. 61, No. 135 / Friday, July 12, 1996 / Notices

Food and Drug Administration

[Docket No. 96M–0219]

Abbott Laboratories; Premarket Approval of Abbott PGR–ICA Monoclonal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application submitted by Abbott Laboratories, Abbott Park, IL, for premarket approval, under the Federal Food, Drug, and Cosmetic Act